NEW YORK, Aug. 19 - As big pharma's product pipeline continues to wither, the role of genomics-tool and -data providers becomes increasingly uncertain.

Will the pressure on pharma firms to develop new products at all costs mean that genomic companies can expect an increase in new-technology orders? Or will pharma's revenue woes mean that increased spending on new technology becomes foolish?

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.